Roche agrees to buy a developer of a drug for people suffering from inflammatory bowel disease from Roivant Sciences and Pfizer in a deal worth up to $7.25 billion, Textainer is being acquired for about $2.1 billion, and Microsoft and Alphabet lead a busy earnings week.
These Stocks Are Moving the Most Today: Roivant Sciences, Textainer, Okta, Microsoft, Alphabet
2023-10-23 16:50
Roche agrees to buy a developer of a drug for people suffering from inflammatory bowel disease from Roivant Sciences and Pfizer in a deal worth up to $7.25 billion, Textainer is being acquired for about $2.1 billion, and Microsoft and Alphabet lead a busy earnings week.
You Might Like...
Deutsche Bank Places New Restrictions on Financing of Coal
Fortnite Acknowledges It Missed The Mark With New Cosmetics Restrictions
Wave Neuro Receives 2023 Restore Technology Award
Marvel told to 'do better' for using AI for 'Secret Invasion' opening sequence
Mark Zuckerberg has lost $40 billion on metaverse, Meta results show – and he plans to lose even more
Caesars and MGM grapple with hacks as cybersecurity in Vegas is under scrutiny
System Initiative Heralds the Second Wave of DevOps with a New Collaborative Power Tool That Rebuilds DevOps from the Ground Up
Reddit goes dark: Why are thousands of the world’s most popular forums shutting down?